shortage of glp-1 receptor agonists The Multi-Sector Impacts GLP-1RA Drugs Metabolic Consequences of Glucagon-Like Peptide-1
Description
J Insur Med
Factor in delivery preferences : For needle-averse patients, oral semaglutide or SGLT2 inhibitors may be easier to accept
In ConclusionEmpowering Midlife Health Through Blood Sugar and GLP-1 Support Managing blood sugar and supporting GLP-1 production is essential for healthy aging
Exclusion criteria: Non-RCTs (cohort, casecontrol, cross-sectional studies, case reports)
DPP-4 inhibitors did not lower the risk of any cardiorenal outcome when compared with placebo and were associated with higher risks of MACE, HHF, and renal outcome when compared with the other two drug classes
